Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Nuvalent (NUVL – Research Report) and keeping the price target at ...

Nuvalent, Inc. (NUVL) reported Loss for its third quarter that increased from the same period last year The company's bottom line ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today highlighted pipeline ...

Year to date, Nuvalent’s shares have surged 42.4% compared with the industry’s 1.0% growth. During this timeframe, the stock has also outperformed the sector and the S&P 500.

Shares of the biotech Nuvalent were up sharply early Monday, after the company unveiled updates on two experimental cancer ...

On Friday, Nuvalent Inc (NUVL) stock saw a modest uptick, ending the day at $89.22 which represents a slight increase of $0.73 or 0.82% from the prior close of $88.49. The stock opened at $89 and ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the ...

Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the stock, Marketbeat reports.

UBS Group began coverage on shares of Nuvalent (NASDAQ:NUVL – Free Report) in a report released on Thursday morning, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $100. ...

Top-performing mid-cap stocks last week. Nuvalent shares are trading lower by 6.2% during Tuesday's session. The company priced a $500 million public offering of 5 million shares at $100 each.

Traders use this information to analyze potential trades and assess market sentiment for Nuvalent. In The Money Expiration Date November 15, 2024 December 20, 2024 January 17, 2025 April 17, 2025 ...